This study is designed in two parts. Part 1 will assess the safety and tolerability of different doses of RLX030 when given to pregnant women with pre- eclampsia (elevated blood pressure with protein in urine). Part 2 will assess whether an optimal dose of RLX030 can prolong pregnancy in women with pre-eclampsia.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
3
Novartis Investigative Site
Mobile, Alabama, United States
Novartis Investigative Site
Lexington, Kentucky, United States
Novartis Investigative Site
Louisville, Kentucky, United States
Novartis Investigative Site
Galveston, Texas, United States
Number of Patients With Adverse Events, Serious Adverse and Death During Part 1 of the Study
Safety and tolerability was assessed by adverse events/serious adverse event and death monitoring.
Time frame: Prior to delivery until 4-6 weeks post partum (maximum of 8 weeks)
Change From Baseline in Maternal Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) in Part 1of the Study (Part 1)
Maternal safety assessment to monitor pre-eclampsia by checking blood pressure during 72 hour treatment period as well as post-dose.
Time frame: From baseline to during treatment period of a maximum 72 hours infusion prior to delivery until 4-6 weeks post partum in part 1 (maximum of 8 weeks)
Change From Baseline in Mean Maternal Arterial Pressure (Part 1)
Maternal safety assessment to monitor pre-eclampsia by checking mean arterial pressure during 72 hour treatment period as well as post-dose.
Time frame: From baseline to during treatment period of a maximum 72 hours infusion prior to delivery until 4-6 weeks post partum in part 1 (maximum of 8 weeks)
Change From Baseline on Maternal Proteinuria (Part 1)
Pre-eclampsia was monitored by checking levels of protein in urine and by urinary protein/creatinine ratio (UPCR)
Time frame: From baseline to during treatment period of a maximum 72 hours infusion prior to delivery until 4-6 weeks post partum in part 1 (maximum of 8 weeks)
Decrease in Utero-placental Blood Flow (Part 1)
Blood flow to the fetus was monitored using via a Doppler.
Time frame: During treatment period of a maximum 72 hours infusion prior to delivery and up to delivery in part 1 (maximum of 3 weeks)
Change in Fetal Heart Rate (Part 1)
Heart rate of fetus was monitored continuously throughout 72 hour treatment period using a cardiotocograph.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Novartis Investigative Site
Modena, MO, Italy
Time frame: During treatment period of a maximum 72 hours infusion prior to delivery and up to delivery in part 1 (maximum of 3 weeks)
Improvement in Renal Function Assessed by Increase in Creatinine Clearance
Time frame: From randomization until 4-6 weeks post partum (maximum 8 weeks)
Rate of Spontaneous Delivery and/or Mode of Delivery
Time frame: From randomization to delivery (maximum of 3 weeks)
Number of Patients With Absence of Anti-serelaxin Antibodies
Time frame: From Randomization until 4-6 weeks post partum (maximum of 8 weeks)
Number of Patients With Abnormalities in Birth Weight, Gestational Age, Appearance, Pulse, Grimace, Activity, Respiration (APGAR) Score, Umbilical Cord Gases, and Days in Neonatal Intensive Care Unit (NICU)
Time frame: up to 4 - 6 weeks post partum (maximum of 8 weeks )
Number of Patients With Abnormalities in Fetal Cardiotocography and Biophysical Profile
Time frame: Randomization to delivery (maximum of 3 weeks)
Pharmacokinetics of RLX030: Area Under the Blood Concentration-time Curve From Time Zero to Infinity (AUCinf)-Part 1
Blood concentrations of RLX-030 was assayed to determine this PK parameter.
Time frame: Baseline, 2, 6, 24,48,72, 76, 80 and 90 hours after initiation of infusion during part 1
Pharmacokinetics of RLX030: Area Under the Blood Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast)-Part 1
Blood concentrations of RLX-030 was assayed to determine this PK parameter.
Time frame: Baseline, 2, 6, 24,48,72, 76, 80 and 90 hours after initiation of infusion during part 1
Pharmacokinetics of RLX030: Blood Concentration at 24 Hour (C 0-24h) After Administration- Part 1
Blood concentrations of RLX-030 was assayed to determine this PK parameter.
Time frame: Baseline, 2, 6, 24,48,72, 76, 80 and 90 hours after initiation of infusion during part 1
Pharmacokinetics of RLX030: Terminal Elimination Half-life (T1/2)- Part 1
Blood concentrations of RLX-030 was assayed to determine this PK parameter.
Time frame: Baseline, 2, 6, 24,48,72, 76, 80 and 90 hours after initiation of infusion during part 1
Pharmacokinetics of RLX030: Mean Residence Time (MRT)
Blood concentrations of RLX-030 was assayed to determine this PK parameter.
Time frame: Baseline, 2, 6, 24,48,72, 76, 80 and 90 hours after initiation of infusion during part 1
Mean Number of Days Before Delivery
Time frame: From randomization until delivery (maximum of 3 weeks)